整理 | GLP1减重宝典内容团队 ▍GLP-1减肥神药，拟被纳入美国医保 8月1日，据外媒报道，特朗普政府正筹备一项试点计划，允许联邦医保（Medicare）和低收入人群医疗补助（Medicaid）覆盖减重药物费用， 目标是通过扩大对GLP-1类药物的可及性，缓解美国日益严重的肥胖问题。 这一举措基于拜登政府在2024年卸任前提出的初步方案。根据《华盛顿邮报》获得的美国医保与医疗补助服务中心（CMS）文件，该试点项目 将允许各州Medicaid和Medicare 的GLP-1药物提供"体重管理"用途的报销支持。 GLP-1类药物最初用于治疗2型糖尿病，因其能够通过抑制食欲、减缓胃排空等机制显著降低体重，近年来被广泛用于肥胖干预。但其高昂费用 （年均约5,000至7,000美元）引发了有关财政可持续性的担忧。 该举措也可能引发政府内部意见分歧。CMS负责人、曾公开支持GLP-1类药物的Mehmet Oz，与对其成本和依赖性提出批评的卫生部长小罗伯 特·F·肯尼迪立场并不一致，后者强调药物不能取代健康的生活方式。 目前， 包括司美格鲁肽（Ozempic、Wegovy）与替尔泊肽（Mounjaro、Zepboun ...

Core Viewpoint - The FDA has approved multiple indications for semaglutide (Ozempic, Wegovy, Rybelsus), particularly focusing on its use in children, elderly, and pregnant women [2]. Summary by Category Use in Children - Wegovy is approved for weight management in obese adults and children aged 12 and above. - Ozempic is indicated as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease [4]. - Wegovy, when combined with a low-calorie diet and increased physical activity, reduces the risk of major adverse cardiovascular events in adults with cardiovascular disease who are obese or overweight, and helps in weight loss and maintenance for obese or overweight adults and children aged 12 and above with at least one weight-related comorbidity [4]. Use in Pregnant Women - Semaglutide may cause harm to the fetus; it should be discontinued upon confirmation of pregnancy [6]. - Women and men of childbearing age should stop using semaglutide at least 2 months prior to planning pregnancy due to its long half-life [7]. - Breastfeeding is not recommended while using semaglutide [8]. Use in Elderly - No overall differences in safety or efficacy were found between Ozempic users aged 65 and older and younger patients, although some elderly individuals may be more sensitive [10]. - Wegovy reported more severe adverse reactions compared to younger adult patients [11]. - Rybelsus showed no overall differences in safety or efficacy between patients aged 65 and older and younger patients [12].